Royalty Pharma (RPRX) Non-Current Debt (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Non-Current Debt data on file, last reported at $9.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt rose 35.32% year-over-year to $9.0 billion; the trailing twelve-month figure through Mar 2026 stood at $9.0 billion (up 35.32% YoY), and the FY2025 full-year result was $9.0 billion, up 17.58% from the prior year.
• Non-Current Debt was little changed at $9.0 billion in Q1 2026, from $9.0 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $9.0 billion in Q1 2026 to a low of $6.1 billion in Q4 2022.
• A 5-year average of $7.1 billion and a median of $7.1 billion in 2022 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt decreased 13.79% in 2024 and jumped 35.32% in 2026, its largest moves.
• Tracing RPRX's Non-Current Debt over 5 years: stood at $6.1 billion in 2022, then increased by 0.27% to $6.1 billion in 2023, then grew by 24.08% to $7.6 billion in 2024, then advanced by 17.58% to $9.0 billion in 2025, then advanced by 0.06% to $9.0 billion in 2026.
• Business Quant data shows RPRX's Non-Current Debt at $9.0 billion in Q1 2026, $9.0 billion in Q4 2025, and $8.6 billion in Q3 2025.